Syneos Health, Inc. announced that Colin Shannon has been appointed Chief Executive Officer, effective immediately. Shannon succeeds Michelle Keefe, who will continue her tenure with Syneos Health as a key member of the Executive Leadership Team. Shannon and Keefe will remain on the Board of Directors.
Shannon brings decades of leadership experience driving growth at global biopharmaceutical solutions organizations. During his 14 years at PRA Health Sciences, Shannon served in executive roles, most recently as Chairman and CEO. During his tenure, he grew the company significantly, leading it through a successful IPO and subsequent sale to ICON plc., where he also served on its Board of Directors.
Prior to PRA Health Sciences, he held various executive roles at Pharmaceutical Product Development Inc. (?PPD?), including EVP of Global Clinical Operations, COO and CFO of Europe and Chief Financial and Administrative Officer for International Operations. Keefe served as CEO of Syneos Health for the last 18 months, driving the Company?s ongoing transformation and leading the organization through the successful going private transaction. As a key member of the Executive Leadership Team, she will remain committed and dedicated to Syneos Health?s employees and customers worldwide.